List of Excipients in Branded Drug CHLORAPREP ONE-STEP

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
CareFusion 213 LLC	CHLORAPREP ONE-STEP	chlorhexidine gluconate and isopropyl alcohol	54365-400	FD&C GREEN NO. 3	2027-04-25
CareFusion 213 LLC	CHLORAPREP ONE-STEP	chlorhexidine gluconate and isopropyl alcohol	54365-400	FD&C YELLOW NO. 6	2027-04-25
CareFusion 213 LLC	CHLORAPREP ONE-STEP	chlorhexidine gluconate and isopropyl alcohol	54365-400	WATER	2027-04-25

Chloraprep One-Step Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

ChloraPrep One-Step is a topical antiseptic applicator containing 2% chlorhexidine gluconate in 70% isopropyl alcohol. Its commercial value comes less from novel excipients than from rapid drying, broad antimicrobial performance, skin tolerability, applicator engineering, packaging compatibility, and workflow efficiency. The strongest opportunities are differentiated delivery systems, controlled tinting, reduced residue, improved pediatric tolerability, and hospital-specific product formats.

What is the formulation of ChloraPrep One-Step?

ChloraPrep One-Step uses a high-alcohol formulation with chlorhexidine gluconate as the persistent antimicrobial component and isopropyl alcohol as the rapidly acting antiseptic component. Purified water is used as the principal inactive solvent in the standard formulation. Some ChloraPrep variants include a colorant to show the application area. [1][2]

Component	Function	Strategic significance
Chlorhexidine gluconate, 2% w/v	Persistent antimicrobial active	Requires chemical and formulation compatibility testing
Isopropyl alcohol, 70% v/v	Rapid antimicrobial active and volatile solvent	Drives drying, flammability, packaging, and skin-tolerability requirements
Purified water	Solvent and formulation balance	Affects solubility, viscosity, drying, and impurity control
Colorant, where applicable	Visual coverage indicator	Creates differentiation but adds extractables, staining, and sensitivity testing
Applicator substrate	Delivery and dose control	Important for wetting, release, coverage, and clinical workflow

The principal formulation constraint is that both chlorhexidine and alcohol are active ingredients. The excipient system cannot materially reduce chlorhexidine availability, accelerate precipitation, compromise alcohol concentration, or delay drying on the skin.

What excipients are suitable for a chlorhexidine and isopropyl alcohol formulation?

Suitable excipients must preserve antimicrobial activity, maintain clarity or controlled appearance, support skin application, and remain stable in a volatile solvent system. The practical excipient set is narrow.

Purified water

Purified water is the baseline solvent. Its quality affects chlorhexidine solubility, pH, conductivity, microbial control, and visible particulate performance. Water-system control is commercially important because the product is applied directly to compromised or surgically prepared skin.

Colorants

A compatible dye can improve application coverage and reduce missed skin areas. The commercial tradeoff is between visual control and residual staining. Colorants must be evaluated for:

• Solubility in the hydroalcoholic system
• Light stability
• Skin staining
• Transfer to surgical drapes and clothing
• Extractables and leachables
• Hypersensitivity and local irritation
• Compatibility with the applicator reservoir and sponge

Colorant-enabled products may command a premium in operating-room and catheter-placement settings, but hospitals may prefer clear formulations where staining is operationally undesirable.

Humectants and emollients

Glycerin, propylene glycol, polyethylene glycol derivatives, and similar ingredients could reduce skin dryness, but they introduce significant formulation and regulatory risks. They may:

• Slow evaporation
• Increase residue
• Alter the wetting profile
• Change chlorhexidine release from the applicator
• Affect alcohol concentration at the skin surface
• Increase interaction with drapes, adhesives, or dressings

These materials are therefore more suitable for a separately developed, clinically validated formulation than for a simple line extension.

Surfactants

Surfactants may improve wetting or spreadability, particularly on hair-bearing or irregular skin. They can also bind chlorhexidine, change micelle behavior, increase irritation, and interfere with antimicrobial testing. Nonionic surfactants generally offer a more plausible development path than anionic surfactants, because anionic materials can form poorly soluble complexes with cationic chlorhexidine.

Anionic excipients should be treated as high-risk candidates unless compatibility and efficacy data establish that they do not reduce free chlorhexidine.

Gelling and thickening agents

A low-viscosity gel could improve residence time and reduce runoff. It could also create safety and usability problems by delaying alcohol evaporation or increasing flammability exposure. A gel format would require evidence that:

1. The alcohol concentration remains within specification.
2. The formulation dries within the intended clinical interval.
3. Chlorhexidine remains available at the skin surface.
4. The gel does not increase pooling under the patient.
5. The product does not interfere with electrosurgery or other ignition sources.
6. The product does not reduce adhesive dressing performance.

A gel is a higher-risk reformulation but may provide meaningful differentiation where runoff and uneven coverage are problems.

How should an excipient strategy be designed for ChloraPrep One-Step?

The preferred strategy is to treat the excipient system as part of an integrated drug-delivery platform rather than as a standalone formulation exercise.

Formulation priorities

Priority	Target	Development implication
Antimicrobial preservation	Maintain chlorhexidine and alcohol activity	Use direct microbiological comparison against the reference product
Rapid drying	Minimize wet contact time	Avoid unnecessary polymers, oils, and high-boiling solvents
Low residue	Reduce interference with dressings and drapes	Evaluate nonvolatile materials carefully
Skin tolerability	Reduce stinging and dryness	Test emollient and humectant candidates only in controlled concentrations
Coverage control	Improve application visibility	Consider validated colorants or applicator geometry
Chemical stability	Prevent precipitation and degradation	Control pH, water quality, light, and container interactions
Packaging stability	Preserve alcohol concentration	Use low-permeability containers and validated seals
Manufacturing control	Ensure reproducible dose delivery	Characterize fill volume, sponge loading, and release profile

The most defensible near-term development path is a low-excipient formulation with optimized water quality, optional colorant, and an improved applicator. A heavily modified formulation increases the likelihood that the product will require a new safety and efficacy package.

What formulation patents could protect a ChloraPrep One-Step competitor?

Protection is more likely to arise from a combination of formulation, applicator, packaging, and use claims than from a broad claim to chlorhexidine in alcohol. The active ingredients are established antiseptics, and broad composition claims would face substantial prior-art exposure.

Potential formulation claim categories

A differentiated product could seek protection for:

• A defined chlorhexidine-to-alcohol concentration range
• A specified pH or pH-control system
• A low-residue hydroalcoholic formulation
• A formulation with a defined drying time
• A colorant system that remains stable in high-concentration alcohol
• A formulation that reduces skin irritation while preserving antimicrobial performance
• A composition with controlled chlorhexidine release from a sponge
• A formulation with specified viscosity, surface tension, or evaporation characteristics

Potential device and packaging claims

Commercially stronger claims may cover:

• A single-use applicator with controlled dose release
• A sponge architecture that improves uniform wetting
• A reservoir that prevents premature alcohol loss
• A frangible package with reduced leakage
• A low-permeability container for hydroalcoholic liquids
• An applicator designed for catheter insertion, surgery, or neonatal use
• A dual-component applicator that separates formulation and colorant until use

A competitor should expect composition claims to be easier to design around than applicator and packaging claims. Freedom-to-operate review must cover U.S., European, Japanese, and other major-market patents involving chlorhexidine applicators, surgical preparation systems, sponge materials, and alcohol-containing antiseptic packaging.

What is the FDA regulatory status of ChloraPrep One-Step?

ChloraPrep is a topical antiseptic drug product used for skin preparation before injections, catheter placement, and surgical procedures. Chlorhexidine gluconate and isopropyl alcohol are recognized topical antiseptic actives under the FDA’s antiseptic regulatory framework, subject to product-specific labeling and evidence requirements. [3][4]

The FDA’s 2016 final rule for over-the-counter consumer antiseptic rubs did not establish that every professional-use antiseptic product could enter the market solely under an OTC monograph. Professional healthcare antiseptic products remain subject to their applicable regulatory pathway, labeling, manufacturing, and evidence requirements. [4]

A formulation change involving only an inactive ingredient may still require substantial regulatory work if it changes:

• Antimicrobial effectiveness
• Drying time
• Skin exposure
• Local irritation
• Sensitization
• Residue
• Delivery dose
• Container closure
• Applicator performance
• Use in pediatric or neonatal populations

The product’s regulatory burden is therefore determined by the total drug-device system, not only the ingredient list.

What is the Orange Book status of ChloraPrep One-Step?

ChloraPrep One-Step is not generally analyzed as a conventional branded prescription tablet or injectable with a standard Orange Book patent-and-exclusivity profile. The product is a topical antiseptic delivered through a single-use applicator, and its commercial protection is more likely to depend on trademarks, manufacturing know-how, device patents, formulation patents, regulatory status, and hospital contracts than on a conventional small-molecule Orange Book listing.

A generic or competing product would face a combination of regulatory and technical barriers:

• Demonstrating equivalent antiseptic performance
• Matching active-ingredient concentrations
• Validating the applicator dose and coverage
• Establishing container-closure integrity
• Managing alcohol flammability requirements
• Reproducing drying and residue characteristics
• Avoiding formulation, device, and packaging patents

When does ChloraPrep One-Step lose exclusivity?

No single patent expiration date defines ChloraPrep One-Step’s loss of exclusivity. The relevant protection may be distributed across formulation patents, applicator patents, packaging patents, trademarks, trade secrets, and customer contracts. Established active ingredients do not by themselves create meaningful product exclusivity.

The most important practical distinction is between:

Protection type	Typical commercial effect
Active-ingredient exclusivity	Limited because chlorhexidine and alcohol are established actives
Formulation patent	Protects defined composition or performance attributes
Applicator patent	Can block a commercially important delivery format
Packaging patent	May constrain reservoir and container design
Trademark	Protects brand identity but does not block equivalent products
Trade secret	Protects manufacturing parameters and quality controls
Regulatory exclusivity	Depends on the applicable approval pathway and product designation
Hospital contract	Can delay conversion even after legal barriers fall

A competing manufacturer can enter before every patent expires if it uses a noninfringing formulation and applicator and satisfies regulatory requirements. Conversely, a technically similar product may remain commercially constrained by device patents, contracts, quality requirements, or customer switching costs.

Which companies compete with ChloraPrep One-Step?

The competitive field includes manufacturers of chlorhexidine-alcohol applicators, povidone-iodine preparations, alcohol-only skin antiseptics, and procedure-specific antiseptic systems.

Competitor category	Representative products or companies	Main differentiation
Chlorhexidine-alcohol applicators	BD ChloraPrep and competing hospital antiseptic suppliers	Persistent activity and workflow
Povidone-iodine products	PDI, Medline, Cardinal Health and other suppliers	Broad use history, iodine-based chemistry
Alcohol-only products	Multiple generic and hospital suppliers	Lower formulation complexity and rapid drying
Antiseptic applicator systems	3M, Medline, Cardinal Health and private-label manufacturers	Applicator design, dose, packaging, contracts
Procedure-specific systems	Hospital-focused suppliers	Catheter placement, surgery, neonatal or orthopedic use

The strongest competitor is not necessarily the product with the closest formulation. Hospitals often evaluate total procedure cost, application time, clinician familiarity, infection-prevention protocols, supply reliability, and contract terms.

What commercial opportunities exist for excipient innovation?

Pediatric and sensitive-skin formulations

A lower-irritancy version could target patients who experience dryness, burning, or skin injury from high-alcohol preparations. The development challenge is preserving rapid antimicrobial activity while reducing local tolerability problems.

Potential approaches include:

• Lower-residue emollients
• Controlled alcohol evaporation
• Reduced application volume
• Alternative applicator substrates
• Procedure-specific pediatric sizes
• Separate labeling for premature infants or other high-risk populations where permitted by evidence

This segment has commercial potential but carries elevated clinical and regulatory risk.

Controlled-coverage products

Tinted formulations and applicators with predictable wetting can reduce missed areas. A controlled-coverage product may be valuable for:

• Central-line insertion
• Surgical preparation
• Orthopedic procedures
• Emergency medicine
• Large-surface preparation
• Training and quality assurance

The value proposition should be measured through coverage accuracy, preparation time, product waste, and protocol compliance.

Low-residue formulations

A low-residue product could improve compatibility with:

• Transparent dressings
• Catheter securement devices
• Surgical adhesives
• Electrosurgical procedures
• Wound-care materials

This opportunity is commercially attractive because it connects excipient design with downstream clinical workflow. Testing must include dressing adhesion, residue transfer, and compatibility after drying.

Extended-wet-time or gel systems

A gel or higher-viscosity system could address runoff and irregular coverage. Its principal risks are delayed drying, pooling, flammability, and interference with adhesives. A gel should be positioned for a defined procedure rather than as a universal replacement.

Sustainable applicator and packaging systems

The largest environmental opportunity may involve the delivery system rather than the liquid formulation. Potential developments include:

• Lower-material reservoirs
• Recyclable outer packaging
• Reduced secondary packaging
• Lower-volume applicators
• Improved shipper density
• Material systems with lower extractables and lower environmental burden

Any change must preserve alcohol retention, sterility or microbial control, mechanical integrity, and safe disposal.

What manufacturing and intellectual-property barriers affect market entry?

The manufacturing process is a material barrier even when the formulation is chemically simple. Critical controls include:

• Accurate alcohol concentration
• Chlorhexidine assay and impurity profile
• Uniform sponge loading
• Fill-volume precision
• Container-closure integrity
• Alcohol evaporation during filling and storage
• Compatibility of dyes, adhesives, seals, and plastics
• Particulate control
• Stability under heat and light
• Shipping performance and leakage resistance

A product can meet nominal concentration specifications and still fail commercially if its applicator delivers an uneven dose or dries too slowly.

Trade secrets may cover mixing order, filling conditions, sponge conditioning, packaging controls, and stability parameters. These process controls can create a practical barrier even where patent protection is limited.

How strong is the patent estate for ChloraPrep One-Step?

The likely strength of the estate is highest around the integrated applicator and packaging system and lower around the basic chlorhexidine-alcohol composition.

Estate component	Relative strength	Reason
Basic 2% chlorhexidine in 70% alcohol composition	Low to moderate	Established chemistry and substantial prior art
Specialized excipient system	Moderate	Strength depends on unexpected performance data
Tinted formulation	Moderate	Claims may be narrow and design-around options exist
Applicator architecture	Moderate to strong	Device geometry can create practical barriers
Packaging and reservoir	Moderate	Commercial importance depends on claim scope
Manufacturing process	Moderate	Trade-secret protection may exceed patent value
Method-of-use claims	Moderate	Stronger when tied to a defined procedure or patient group
Brand and hospital contracts	Commercially strong, legally distinct	Can delay substitution without patent exclusion

Patent strength should be assessed claim by claim. A narrow claim covering a specific viscosity, dye concentration, substrate, and drying time may be difficult to invalidate but easy to design around. A broader applicator claim may have more commercial value if it covers the dominant delivery format.

What generic launch risks exist for ChloraPrep One-Step?

A competing product could pursue several launch strategies:

1. Match the active ingredients but use a different applicator.
2. Use a clear formulation instead of a tinted formulation.
3. Develop a different excipient system with equivalent antimicrobial performance.
4. Target a procedure-specific market, such as catheter preparation.
5. Launch a private-label hospital product.
6. Compete first in jurisdictions with lower switching barriers.
7. Use a povidone-iodine or alcohol-based alternative where protocol permits.

The highest-risk launch scenario for the incumbent is a noninfringing product that matches drying time, coverage, antimicrobial performance, and packaging reliability while offering lower acquisition cost. A product that merely matches the active ingredients but performs poorly in application is less likely to displace ChloraPrep in institutional accounts.

Key Takeaways

• ChloraPrep One-Step is built around 2% chlorhexidine gluconate and 70% isopropyl alcohol.
• The excipient system is intentionally narrow because added ingredients can reduce antimicrobial performance, increase residue, slow drying, or increase irritation.
• The most practical formulation opportunities are compatible colorants, low-residue systems, controlled wetting, and carefully selected skin-tolerability excipients.
• Applicator, reservoir, packaging, and manufacturing patents may provide more valuable protection than broad composition claims.
• ChloraPrep’s competitive protection is not defined by a single Orange Book patent expiration date.
• The strongest commercial opportunities are procedure-specific products, pediatric or sensitive-skin variants, low-residue formulations, and improved applicator systems.
• Generic entry risk depends on the full drug-device system, not only on reproducing the active-ingredient concentrations.

FAQs

Can glycerin be added to ChloraPrep One-Step?

Glycerin could improve skin feel but may slow drying, increase residue, alter alcohol evaporation, and affect chlorhexidine release. It would require formulation, antimicrobial, irritation, adhesive-compatibility, and stability testing.

Could a competitor replace isopropyl alcohol with ethanol?

Yes, a competitor could develop an ethanol-based antiseptic, but it would need to establish equivalent antimicrobial performance, drying behavior, skin tolerability, labeling, packaging compatibility, and regulatory acceptability. It would not necessarily be a direct formulation substitute.

Is chlorhexidine gluconate compatible with anionic surfactants?

Compatibility is generally problematic because chlorhexidine is cationic and can interact with anionic materials. Any anionic surfactant would require direct precipitation, assay, antimicrobial, and stability testing.

Does a tinted ChloraPrep formulation create meaningful patent value?

It can, especially when the colorant is linked to stable coverage indication, low staining, rapid drying, or a defined applicator system. Broad colorant claims are more vulnerable to design-around strategies than claims tied to a specific formulation and delivery architecture.

What is the most defensible commercial reformulation strategy?

A low-residue, rapidly drying formulation paired with a controlled-coverage applicator is the most defensible near-term strategy. It improves workflow without adding the risks associated with a highly viscous gel or heavily modified excipient system.

References

1. Becton, Dickinson and Company. (n.d.). ChloraPrep One-Step drug facts and product labeling.
2. National Library of Medicine. (n.d.). DailyMed: Chlorhexidine gluconate and isopropyl alcohol topical antiseptic labeling. U.S. National Library of Medicine.
3. U.S. Food and Drug Administration. (2022). OTC monograph M003: Topical antiseptic drug products for over-the-counter human use.
4. U.S. Food and Drug Administration. (2016). Safety and effectiveness of consumer antiseptic rubs; topical antimicrobial drug products for over-the-counter human use. Federal Register, 81 Fed. Reg. 61106.
5. Centers for Disease Control and Prevention. (2011). Guidelines for the prevention of intravascular catheter-related infections. U.S. Department of Health and Human Services.